Silverback Therapeutics to Present Data on Two Programs at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting

November 9, 2020

— Trial-in-progress update on the Phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to TLR8 agonist, in subjects with advanced HER2-expressing solid tumors

— Preclinical data on SBT6290, a Nectin4-directed monoclonal antibody conjugated to a TLR8 agonist

SEATTLE—(BUSINESS WIRE)—Silverback Therapeutics, Inc. (“Silverback”) (“the Company”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue-targeted therapeutics, will present two posters at The Society for Immunotherapy of Cancer’s (SITC) Annual Meeting from November 9-14, 2020.

Silverback Therapeutics to present data on two programs at the Society for Immunotherapy of Cancer’s (SITC) 35th anniversary annual meeting.

Tweet this

Silverback will present a trial-in-progress update on SBT6050-101, a Phase 1/1b dose-escalation and expansion clinical trial in patients with advanced or metastatic HER2-expressing solid tumors. SBT6050, the Company’s lead product candidate, comprises a TLR8 linker-payload conjugated to a HER2-directed monoclonal antibody for tumor-localized activation of myeloid cells. “Patients with HER2-expressing cancers need new therapeutic options after standard therapies fail. Most will not respond to PD-1/PD-L1 inhibitors, and physicians and patients are interested in novel immunotherapy options. The SBT6050-101 trial is the first step forward to assess whether Silverback’s novel approach could benefit patients,” said Naomi Hunder, M.D., chief medical officer of Silverback. “In preclinical studies, SBT6050 had a favorable toxicity profile, and induced a broad spectrum of antitumor immune mechanisms.” SBT6050-101 is actively enrolling in the US and Australia (ClinicalTrials.gov Identifier: NCT04460456).

In addition, the Company will present preclinical data on SBT6290, its second product candidate comprised of the same TLR8 linker-payload used in SBT6050 conjugated to a Nectin4-specific monoclonal antibody. “Nectin4 is a clinically-validated target that is expressed in subsets of solid tumors including bladder, triple negative breast, head and neck, and non-small cell lung cancers among others,” said Valerie Odegard, Ph.D., president & chief scientific officer of Silverback Therapeutics. “We are encouraged by SBT6290’s preclinical profile to date and anticipate submitting an IND for this program in the fourth quarter of 2021.”

Details of the poster presentations are as follows. The full abstracts will be made available on the SITC website on November 9, 2020.

A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors
Abstract Number: 317
Virtual Poster Hall
Presenter: Leisha Emens, MD, Ph.D., University of Pittsburgh Hillman Cancer Center
Session Date & Time: Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST
Category: Clinical Trial in Progress

SBT6290, a Systemically Administered Nectin4-Directed TLR8 ImmunoTAC Therapeutic, is a Potent Human Myeloid Cell Agonist For the Treatment of Nectin4-Expressing Tumors
Abstract Number: 712
Virtual Poster Hall
Presenter: Heather Metz, Ph.D., Silverback Therapeutics
Session Date & Time: Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST
Category: Novel Single-Agent Immunotherapies

About Silverback Therapeutics

Silverback Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno- oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback’s lead product candidate, SBT6050, is a therapeutic comprised of a TLR8 agonist payload conjugated to a HER2-directed monoclonal antibody that targets tumors such as breast, gastric and non-small cell lung cancers. SBT6050 is currently in a Phase 1 clinical study in patients with advanced or metastatic HER2-expressing solid tumors (ClinicalTrials.gov Identifier: NCT04460456). Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.

Contacts
Steve E. Kunszabo
Canale Communications